Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 18/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27801911 | 0.84 | CDK2 (0.43) | CDK2 | |
| SCHEMBL28114489 | 0.82 | CDK2 (0.42) | CDK2 | |
| SCHEMBL24696515 | 0.82 | MEN1 (0.46) | CDK2 | |
| SCHEMBL30041042 | 0.82 | MEN1 (0.46) | CDK2 | |
| SCHEMBL28129725 | 0.81 | HSD11B1 (0.37) | CDK2IDO1 | |
| SCHEMBL28311619 | 0.81 | IDO1 (0.57) | CDK2PTPN1IDO1 | |
| SCHEMBL15416935 | 0.79 | CDK2 (0.44) | CDK2 | |
| SCHEMBL28867242 | 0.78 | TRPA1 (0.41) | CDK2IDO1 | |
| SCHEMBL24696655 | 0.77 | CDK2 (0.42) | CDK2IDO1 | |
| SCHEMBL21494230 | 0.77 | CDK2 (0.48) | CDK2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017512-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| EP-3882247-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-09-22 | — | — | EP | disclosed |
| CN-110003214-A | Substituted pyrazolo [1,5-a] pyrimidine compound as TRK kinase inhibitor | 阵列生物制药公司 | 2019-07-12 | — | — | CN | disclosed |
| CN-109824566-A | The synthetic method of one kind (R) -2- (2,5- difluorophenyl) pyrrolidines | 浙江师范大学 | 2019-05-31 | — | — | CN | disclosed |
| CN-109593802-A | The preparation method of one kind (R) -2- (2,5- difluorophenyl) pyrrolidines or its salt | 上海健康医学院 | 2019-04-09 | — | — | CN | disclosed |
| CN-109593803-A | (R) preparation method of -2- (2,5- difluorophenyl) pyrrolidines or its salt | 上海健康医学院 | 2019-04-09 | — | — | CN | disclosed |
| CN-109414442-A | (S) liquid preparation of-N- (5- ((R) -2- (2,5- difluorophenyl)-pyrrolidin-1-yl)-pyrazolo [1,5-A] pyrimidin-3-yl) -3- hydroxyl pyrrolidine -1- formamide | 洛克索肿瘤学股份有限公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-109310694-A | METHODS OF TREATING PEDIATRIC CANCERS | 洛克索肿瘤学股份有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-106008523-B | Substituted pyrazolo [1,5-a] pyrimidine compound as TRK kinase inhibitor | 阵列生物制药公司 | 2019-01-25 | — | — | CN | disclosed |
| CN-108484361-A | (S) the chloro- 1- of -4- (2,5)-difluorophenyl butyl- 1- alcohol and its preparation method and application | 上海弈柯莱生物医药科技有限公司 | 2018-09-04 | — | — | CN | disclosed |
| CN-108218754-A | A kind of preparation method of 2- (2,5- difluorophenyls) pyrrolidines | 广东赛烽医药科技有限公司 | 2018-06-29 | — | — | CN | disclosed |
| CN-108003161-A | Neurotrophic factor tyrosine kinase receptor inhibitor | 正大天晴药业集团股份有限公司 | 2018-05-08 | — | — | CN | disclosed |
| CN-107428760-A | Crystalline forms of (S) -N- (5- ((R) -2- (2, 5-difluorophenyl) -pyrrolidin-1-yl) -pyrazolo [1,5-a ] pyrimidin-3-yl) -3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | 阵列生物制药公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-107286070-A | Synthesis method and intermediate of (R) -2- (2, 5-difluorophenyl) pyrrolidine | 浙江师范大学 | 2017-10-24 | — | — | CN | disclosed |
| CN-107207514-A | Fused heteroaryl compounds and their use as TRK inhibitors | 康联制药有限公司 | 2017-09-26 | — | — | CN | disclosed |
| EP-3157921-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | Dr. Reddy's Laboratories Ltd. (IN) | 2017-04-26 | — | — | EP | disclosed |
| CN-104114553-B | Substituted pyrazolo [1,5 a] pyridine as tropomyosin receptor kinase (Trk) inhibitor | 雷迪博士实验室有限公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-106008523-A | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | 阵列生物制药公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-103965200-B | As imidazo [1,2-B] pyridazine compound of the replacement of TRK kinase inhibitor | 阵列生物制药公司 | 2016-06-08 | — | — | CN | disclosed |
| WO-2015200341-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017512-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | GRK6, ERBB2, ERBB3 | CDK2 295/4885PTPN1 846/4885IDO1 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.